InvestorsObserver
×
News Home

Merus N.V. CS Down 9.19% To $25.58 After Earnings Beat

Tuesday, August 09, 2022 12:31 PM | InvestorsObserver Analysts

Mentioned in this article

Merus N.V. CS Down 9.19% To $25.58 After Earnings Beat

Tuesday, August 9, 2022 - Merus N.V. CS (MRUS) reported upside earnings and revenues today.

Merus N.V. CS's earnings came in at an EPS loss of $0.13 per share, 79.00% higher than estimates for an EPS loss of $0.61 per share. The firm's loss per share narrowed by 82% since reporting a loss of $0.71 per share a year ago. Remember, earnings reported were on an adjusted basis, so they may not be comparable to prior reports and/or analyst estimates.

Consensus estimates for Merus N.V. CS revenue averaged out to $10.4 million, with the business managing to beat those expectations with reported second-quarter revenue of $12.7 million. The $2.3 million (22%) positive revenue surprise led to 2% growth year-over-year as the firm reported revenue of $12.4 million in its year-ago quarter. The higher earnings growth compared to revenue points to Merus N.V. CS improving its profit margin.

The stock is down 9.19% to $25.58 after the report.

The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

Trading in the five days leading up to the report earned Merus N.V. CS a Bullish Sentiment Rank from InvestorsObserver.

Merus N.V. CS has been a strong performer over the past few months, garnering a high Long-Term Technical Rank by InvestorsObserver of 89, putting Merus N.V. CS in the top 25% of stocks. The firm was recently trading at a 52-week low of $13.47 on May 26, 2022 and set a 52-week high on December 31, 2021 at $33.09.

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App